SpartaLabs
0
SpartaLabs Research · June 17, 2026

IGF-1 LR3: A Research Overview

A research-library overview of IGF-1 LR3 — molecular structure, pharmacological classification, IGFBP-binding properties, and regulatory status. Educational reference.

igf-1-lr3igf-1insulin-like-growth-factorigfbpreceptor-tyrosine-kinase

Introduction

IGF-1 LR3, formally designated Long Arginine-3 Insulin-like Growth Factor-1, is a synthetic analog of native human insulin-like growth factor-1 (IGF-1) designed specifically as a precision pharmacological tool for receptor biology research. The molecule retains high-affinity engagement of the type 1 IGF receptor (IGF-1R) while exhibiting substantially reduced affinity for the IGF-binding protein (IGFBP) family — a property that has made it a foundational research reagent for studying receptor-proximal signaling in isolation from the confounding influence of endogenous binding proteins. This article provides an educational reference overview of IGF-1 LR3's chemical identity, pharmacological classification, and regulatory status.

Background

The insulin-like growth factor system comprises two ligands (IGF-1 and IGF-2), two primary receptors (IGF-1R and the mannose-6-phosphate/IGF-2 receptor), and a family of at least six high-affinity binding proteins designated IGFBP-1 through IGFBP-6. In typical physiological contexts, the large majority of circulating IGF-1 — estimated at approximately 98% — exists in complex with one or more IGFBPs, which modulate the ligand's bioavailability, half-life, and access to cellular receptors [1].

This extensive sequestration creates an experimental challenge: when native IGF-1 is added to biological systems retaining endogenous IGFBPs, a substantial fraction is captured before reaching the receptor. IGF-1 LR3 was engineered to solve that problem — enabling investigators to interrogate IGF-1R biology with a defined, minimally-sequestered ligand. Its design has produced one of the most widely-used recombinant research tools for the IGF axis across cell-culture and animal-model disciplines.

Chemistry and Structure

IGF-1 LR3 is a recombinant 83-amino acid peptide. Its sequence differs from native 70-amino acid human IGF-1 in two key respects. First, the peptide carries a 13-amino acid N-terminal extension absent in the mature endogenous form. Second, the glutamic acid residue at position 3 is substituted with arginine — the modification giving the molecule its "R3" designation [2].

These two structural alterations together confer the molecule's defining pharmacological characteristic: dramatically reduced affinity for the IGFBP family. Studies published in the 1990s established that the affinity of LR3IGF-I for IGFBPs — including IGFBP-1, IGFBP-2, and IGFBP-3 — is at least three orders of magnitude lower than that of native IGF-1 [3]. Because IGFBPs bind endogenous IGF-1 with affinity equal to or exceeding that of IGF-1R itself, this reduction fundamentally alters the analog's experimental behavior compared with native IGF-1.

Despite these sequence differences, IGF-1 LR3 retains high-affinity binding at the IGF-1R extracellular domain, preserving the capacity to engage and activate the receptor's intracellular tyrosine kinase domain [4]. The molecular weight is approximately 9.1 kilodaltons, somewhat larger than native IGF-1 at approximately 7.6 kilodaltons, reflecting the N-terminal extension.

Pharmacological Classification

IGF-1 LR3 is classified as a synthetic analog of IGF-1, a member of the insulin superfamily of peptide growth factors. The insulin superfamily encompasses insulin, IGF-1, IGF-2, and related peptides that share conserved structural features including disulfide-bonded A, B, C, and D domains, engaging members of the insulin receptor family of receptor tyrosine kinases.

The principal pharmacological distinction of IGF-1 LR3 from SpartaLabs compared with native IGF-1 lies not in receptor selectivity — both bind preferentially to IGF-1R — but in the degree to which circulating or extracellular binding proteins can sequester the ligand. Several comparative studies documented that the reduced sequestration profile translates into substantially greater biological potency per unit mass in cell-culture and animal-model assays when compared with equimolar native IGF-1 [3, 5], making it a high-efficiency probe for receptor pharmacology experiments.

At concentrations substantially exceeding those needed for IGF-1R half-maximal activation, IGF-1 LR3 has been reported to engage the insulin receptor (IR) and heterotetrameric IGF-1R/IR hybrid receptors. Andersen and colleagues (2007) reported that in HEK293 cell cultures, Long R3IGF-I activated IR signaling at lower concentrations than the molecule's low inherent IR affinity alone would predict, an observation the authors attributed to the presence of hybrid receptor complexes [4]. At concentrations optimized for IGF-1R research, receptor selectivity is the primary pharmacological profile.

Regulatory Status

IGF-1 LR3 is used as a research reagent in non-clinical contexts. It does not hold approval from the United States Food and Drug Administration (FDA) or any comparable international regulatory authority for human therapeutic use.

The closely related clinical molecule is mecasermin (Increlex), which is recombinant human IGF-1 (native sequence) carrying FDA approval for growth failure in children with severe primary IGF-1 deficiency (NDA 021839) [6]. For a broader view of growth-hormone-axis analogs with distinct receptor pharmacology, the tesamorelin research overview covers a GHRH analog whose downstream biology intersects the GH/IGF axis at a different regulatory node. Mecasermin's approval affirmed the physiological significance of IGF-1 receptor engagement in human growth biology and the therapeutic viability of recombinant IGF-1-class compounds — a regulatory milestone that contextualizes the receptor pharmacology being studied with IGF-1 LR3 as a research tool. The two molecules are structurally and pharmacologically distinct; mecasermin is native-sequence IGF-1 and does not carry the LR3 modifications.

IGF-1 LR3 has been catalogued in the FDA's Unique Ingredient Identifier (UNII) database — assigned UNII M9L22Y19H9 — consistent with its status as a chemically defined substance. UNII assignment reflects chemical characterization and does not confer or imply regulatory review or approval for human use.

Discovery History

The design of IGF-1 LR3 emerged from research programs in Australia during the late 1980s and early 1990s aimed at creating IGF-1 analogs with modified IGFBP-binding properties. Francis and colleagues published the foundational characterization of the Long R3 variant in the early 1990s, establishing the structural basis for its reduced binding-protein affinity and preserved receptor-binding activity [2]. The compound was subsequently produced and supplied as a research reagent by GroPep Ltd (Adelaide, South Australia), whose name appears in numerous peer-reviewed publications from the 1990s and 2000s identifying it as the source material for LR3IGF-I in published experiments.

Early in vivo studies employing IGF-1 LR3 contributed to understanding how the IGF axis regulates fetal organ development, postnatal growth, and cellular responses in tissue models. These applications are described in depth in the IGF-1 LR3 mechanism of action article in this library.

References

  1. Allard JB, Duan C. IGF-binding proteins: why do they exist and why are there so many? Front Endocrinol (Lausanne). 2018;9:117. PMID: 29686647. DOI: 10.3389/fendo.2018.00117

  2. Francis GL, McNeil KA, Wallace JC, Ballard FJ, Bhatt M. Characterisation of insulin-like growth factor (IGF) analogues with modified affinities for IGF binding proteins. J Mol Endocrinol. 1992;8(3):213-23. PMID: 1534540. DOI: 10.1677/jme.0.0080213

  3. Tomas FM, Lemmey AB, Read LC, Ballard FJ. Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection. J Endocrinol. 1996;150(1):77-84. PMID: 8708565. DOI: 10.1677/joe.0.1500077

  4. Andersen DC, Storling J, Lindberg AM, et al. LONG R3IGF-I as a more potent alternative to insulin in serum-free culture of HEK293 cells. Mol Biotechnol. 2007;34(2):201-12. PMID: 17172665. DOI: 10.1385/MB:34:2:201

  5. Conlon MA, Tomas FM, Owens PC, Wallace JC, Howarth GS, Ballard FJ. Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig. J Endocrinol. 1995;146(2):247-53. PMID: 7561636. DOI: 10.1677/joe.0.1460247

  6. US Food and Drug Administration. Increlex (mecasermin) injection: NDA 021839 prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021839s033lbl.pdf

Frequently asked questions

  • What is IGF-1 LR3?

    IGF-1 LR3, formally designated Long Arginine-3 Insulin-like Growth Factor-1, is a synthetic analog of native human IGF-1 engineered as a precision pharmacological tool for receptor biology research. It retains high-affinity engagement of the type 1 IGF receptor (IGF-1R) while exhibiting substantially reduced affinity for the IGF-binding protein (IGFBP) family.

  • How does IGF-1 LR3 differ structurally from native IGF-1?

    IGF-1 LR3 is a recombinant 83-amino acid peptide, compared with native IGF-1 at 70 amino acids. It carries a 13-amino acid N-terminal extension and an arginine substitution at position 3 (replacing glutamic acid) — the "R3" designation. Together these modifications reduce IGFBP-binding affinity by at least three orders of magnitude while preserving IGF-1R binding.

  • Is IGF-1 LR3 FDA approved?

    IGF-1 LR3 does not hold FDA approval or approval from any comparable international regulatory authority for human therapeutic use. It is used as a research reagent in non-clinical contexts. The closely related clinical molecule is mecasermin (Increlex), which is native-sequence recombinant human IGF-1 with FDA approval for growth failure in children with severe primary IGF-1 deficiency.

  • What is the IGFBP family and why does binding affinity matter for research?

    The IGF-binding protein (IGFBP) family comprises at least six high-affinity proteins that sequester approximately 98% of circulating IGF-1, modulating its bioavailability and receptor access. Because IGFBPs bind native IGF-1 with affinity equal to or exceeding IGF-1R itself, a substantial fraction of added native IGF-1 in experimental systems is captured before reaching the receptor. IGF-1 LR3's dramatically reduced IGFBP affinity allows investigators to study receptor-proximal signaling with minimal confounding by endogenous binding proteins.

  • Who developed IGF-1 LR3 and when?

    IGF-1 LR3 was developed by Francis and colleagues at the University of Adelaide and associated Australian institutions in the late 1980s and early 1990s. The foundational characterization was published in the early 1990s, establishing the structural basis for the analog's reduced binding-protein affinity. The compound was subsequently produced and supplied as a research reagent by GroPep Ltd (Adelaide, South Australia).